Articles
16 June 2009
Vol. 1 No. 7: Chronic Lymphocytic Leukemia: Achievements and Controversies
https://doi.org/10.4081/hmr.v1i7.630

Second line treatment for relapsed chronic lymphocytic leukemia

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
203
Views
1363
Downloads

Authors

Giuseppe Rossi
support@pagepress.org
In spite of the remarkable therapeutic achievements obtained with purine analogues and monoclonal antibodies, chronic lymphatic leukaemia (CLL) has still to be considered an incurable disease. Indeed, in the vast majority of patients, the natural history of the disease is characterized by multiple relapses and by multiple remissions, induced by the potential treatments available.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Second line treatment for relapsed chronic lymphocytic leukemia. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(7). https://doi.org/10.4081/hmr.v1i7.630